Logo

Genomics England: Chris Wigley

Jul 30, 2019

Chris Wigley has been appointed as CEO of Genomics England, effective October 1. He will replace current interim CEO Sir Mark Caulfield, who will remain the firm's chief scientist. Wigley will join Genomics England, which is wholly owned by the UK's Department of Health & Social Care, from QuantumBlack, a machine learning and artificial intelligence company, where he was chief operating officer. Prior to that, he was a partner at McKinsey, and before that, a diplomat with the British Foreign Office.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.